MicroStockProfit.com announces an investment report featuring Hemispherx BioPharma Inc. (AMEX:HEB). The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.
HEB's recent volatility has been greater than normal. This is evidenced by the increased distance between the upper and lower Bollinger Bands. These bands measure volatility using standard deviation and a large width is due to high volatility. Additionally, HEB is trading within its Bollinger Bands. This is a normal condition and suggests that the stock is neither overbought nor oversold relative to the recent price action.
Hemispherx BioPharma Inc. (HEB) is a biopharmaceutical company engaged in the clinical development, manufacture, marketing and distribution of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's products include Ampligen and Alferon N Injection. Ampligen is an experimental drug undergoing clinical development for the treatment of Chronic Fatigue Syndrome (CFS) and as a vaccine enhancer (adjuvant) for both therapeutic and preventative vaccine development. Alferon N is an indicator for refractory or recurring genital warts. Alferon LDO (Low Dose Oral) is an application under early stage development targeting influenza and viral diseases. Ampligen is an experimental drug undergoing clinical development for the treatment of CFS.
Message Board Search for HEB: http://www.boardcentral.com/boards/HEB
In the report, the analyst notes: